Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742960 | 0.81 | ADORA2A (0.39) | ADORA2ACTSKADORA2BADORA1ADORA3 | |
| SCHEMBL5741833 | 0.75 | ADORA1 (0.44) | ADORA2ACTSKADORA2BADORA1ADORA3 | |
| SCHEMBL5741805 | 0.73 | ADORA3 (0.53) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5231865 | 0.67 | ADORA2A (0.64) | ADORA2AADORA2BADORA1ADORA3MEN1 | |
| SCHEMBL5741322 | 0.66 | PDE5A (0.46) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5227169 | 0.64 | ADORA1 (0.65) | ADORA2AADORA2BADORA1ADORA3MEN1 | |
| SCHEMBL6093638 | 0.63 | ADORA1 (0.65) | ADORA2AADORA2BADORA1ADORA3MEN1 | |
| SCHEMBL5741533 | 0.63 | ADORA1 (0.50) | ADORA2ACTSKADORA2BADORA1ADORA3 | |
| SCHEMBL6093414 | 0.61 | ADORA1 (0.61) | ADORA2AADORA2BADORA1ADORA3MEN1 | |
| SCHEMBL5742210 | 0.60 | ADORA2B (0.60) | ADORA2AADORA2BADORA1ADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252780-A1 | Fused pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637532-A1 | FUSED PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252780-A1 | Fused pyrimidine derivatives | INSR, GPR119, NPY4R | ADORA2A 1417/4885CTSK 4529/4885ADORA2B 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.